Biological Complex I (Variolinum)
Brand Names: Biological Complex I
Methodology & AI Transparency ⓘ
Biological Complex I (Variolinum) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Biological Complex I is a over-the-counter branded live vaccinia virus vaccine product delivering active pharmaceutical ingredient Variolinum, registered by Deseret Biologicals, Inc.
- 2 Real-world patient consensus: Biological Complex I links directly to generic Variolinum under FDA SPL 2017-02-08 (NDC 43742-0970).
- 3 Typical cash cost range: Dispensing cost comparison spans $174.10 mail/discount cash up to $461.36 uninsured retail (federal NADAC $2.3000).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Biological Complex I (Variolinum) include headache (11.2%), fatigue (6.7%), vomiting (6.2%).
Ask our AI Specialists anything about Biological Complex I (Variolinum)
Biological Complex I (Variolinum) Mechanism, CYP450 Pathways & DailyMed Monograph
Biological Complex I is a over-the-counter branded live vaccinia virus vaccine product delivering active pharmaceutical ingredient Variolinum, registered by Deseret Biologicals, Inc. under NDC 43742-0970. Updated in FDA DailyMed SPL on 2017-02-08, this branded presentation (30 [hp_C]/mL Liquid; Stepwise Variolinum titration guided by clinical response and eGFR) supports HOMEOPATHIC INDICATIONS: For temporary relief of symptoms of smallpox, such as flu, discomfort, headache, fatigue and.
Pharmacologically, Biological Complex I derives its clinical activity from Variolinum, a live vaccinia virus vaccine molecule with class-characteristic hepatorenal disposition. Branded finished-dosage manufacturing (30 [hp_C]/mL Liquid; Stepwise Variolinum titration guided by clinical response and eGFR; registered by Deseret Biologicals, Inc.) governs excipient dissolution and release kinetics while maintaining bioequivalence benchmarks relative to reference Variolinum (CMS NADAC $2.3000/unit vs. $461.36 retail).
With Approximately 3–14 hours terminal plasma half-life for Biological Complex I (Variolinum) residence kinetics and Estimated 57%–69% oral systemic absorption for Biological Complex I (Variolinum) bioavailability, Biological Complex I (Variolinum) undergoes phase i/ii hepatic conjugation of biological complex i (variolinum) coupled with glomerular and tubular renal excretion and establishes therapeutic activity over peak plasma concentration (tmax) reached 1–3 hours post-dose for biological complex i (variolinum).
Standard adult regimens span 30 [hp_C]/mL Liquid, Stepwise Variolinum titration guided by clinical response and eGFR. Prescribers screen specifically against prior anaphylaxis, angioedema, or severe hypersensitivity to variolinum or biological complex i (variolinum) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2017-02-08 biological complex i (variolinum) spl, while community micro-logs most frequently note headache (11.2% of reports), nausea (7.5% of reports), fatigue (6.7% of reports).
Avoid overlapping live vaccinia virus vaccine prescriptions alongside Biological Complex I (Variolinum) to prevent cumulative receptor toxicity.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Biological Complex I (Variolinum) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Variolinum or Biological Complex I (Variolinum) excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2017-02-08 Biological Complex I (Variolinum) SPL
Logged Side-Effect Incidence (8 Reports)
Biological Complex I (Variolinum) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Biological Complex I (Variolinum))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Type 2 diabetes accelerates brain aging and cognitive decline: Complementary: What a 20,314-Participant Study Found The neurocognitive impact of T2DM suggests marked acceleration of normal brain aging. eLife • 2022-05-24 • Meta-Analysis | N = 20,314 | 94/100 | PMID 35608247 ↗ |
| New Insights on Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA: What a 642-Participant Study Found In this trial of patients with active PsA who had inadequate response or intolerance to at least one biologic DMARD, upadacitinib 15 mg and 30 mg was more effective than placebo over 24 weeks in improving signs and symptoms of... Annals of the rheumatic diseases • 2021-03-15 • Phase III Randomized Trial | N = 642 | 93/100 | PMID 33272960 ↗ |
| New Insights on Population how the body absorbs the medicine and how the medicine works in the: What a 961-Participant Study Found PK/PD modeling showed that single-dose depemokimab 100 mg provides durable BEC reduction throughout a 26-week dosing interval, suggesting sustained suppression of IL-5 activity. Journal of clinical pharmacology • 2026-08-15 • Phase III Randomized Trial | N = 961 | 93/100 | PMID 42530228 ↗ |
| New Insights on Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone: What a 700-Participant Study Found Paliperidone concentration-time profiles after PP6M and PP3M dosing were adequately described by the popPK model. European journal of drug metabolism and pharmacokinetics • 2024-07-15 • Phase III Randomized Trial | N = 700 | 93/100 | PMID 38769284 ↗ |
| What the Latest Evidence Really Says About Placebo response in phase 2 and 3 trials of systemic and biological therapies for At week 12, the pooled proportion of placebo-treated AD patients that obtained EASI50, EASI75 and EASI90 was significantly higher than the pooled proportion of placebo-treated psoriasis patients obtaining PASI50, PASI75 and... Journal of the European Academy of Dermatology and Venereology : JEADV • 2020-06-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 31856331 ↗ |
Biological Complex I (Variolinum) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.3000/unit (~$69.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $461.36 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $174.10 / mo | View logs ↓ |
Biological Complex I (Variolinum) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Biological Complex I (Variolinum) RxNorm Concept ID | RXN-B437420970 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.3000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $461.36 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $174.10 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Biological Complex I (Variolinum) Patient Community, Cohort Filters & Dosage Logs
Deterministic Biological Complex I (Variolinum) reference combining NIH RxNorm (RXN-B437420970), Medicaid NADAC ($2.3000/unit), and anonymous cohort outcomes (86% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Biological Complex I (Variolinum) community threads and patient logs by age, biological sex, dosage, and treatment duration.